Further, inhibitors of SRC family PTK may be clinically useful against KMT2A/MLL-R+ B-ALL and inhibitors of BTK, SYK, and JAK family PTK may be clinically useful against KMT2A/MLL-R+ AML. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.